Commerzbank restated their buy rating on shares of Qiagen (NYSE:QGEN) in a research note released on Thursday morning.

A number of other equities analysts also recently issued reports on QGEN. DZ Bank reaffirmed a neutral rating on shares of Qiagen in a research report on Thursday, April 5th. Morgan Stanley reduced their price target on Qiagen from $39.00 to $37.00 and set an overweight rating on the stock in a research report on Wednesday, April 11th. Deutsche Bank reaffirmed a buy rating and set a $40.00 price target (up from $38.00) on shares of Qiagen in a research report on Tuesday, April 24th. Finally, ValuEngine raised Qiagen from a hold rating to a buy rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Qiagen has a consensus rating of Buy and an average target price of $38.50.

Shares of QGEN stock opened at $34.31 on Thursday. The firm has a market cap of $7,830.71, a PE ratio of 27.02, a price-to-earnings-growth ratio of 2.16 and a beta of 1.03. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07. Qiagen has a 12-month low of $30.20 and a 12-month high of $36.34.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with's FREE daily email newsletter.